Background/Objectives: Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis and complex diagnostic pathways. Pulmonologists often play a central role in its initial recognition and investigation. This narrative review synthesizes the current evidence on [mesothelioma diagnosis], with emphasis on imaging, tissue … [Read more...]
Andexxa Risks Outweigh Its Benefits, Says FDA In December 2025
When AstraZeneca asserted that their recent Andexxa drug recall had to do with “commercial reasons”, we suggested that there was an Andexxa drug safety issue involved, also, in our December 15, 2025, Drug Injury Watch post, "Andexxa Drug Recall December 2025 Due In Part To Safety Issue That Involves Blood Clots". And this December 18, 2025, FDA … [Read more...]
Global burden of lung cancer attributable to occupational asbestos exposure: 1990 to 2021
Background: Asbestos is a well-established occupational carcinogen, with strong evidence linking its exposure to lung cancer. Despite increasing awareness of its health risks, asbestos continues to be used in many countries. We aimed to evaluate the global burden of lung cancer attributable to occupational asbestos exposure and to analyze its … [Read more...]
Wegovy and Ozempic Eye Damage Compensation In Europe, Is US Next?
Drug injury lawsuits seeking compensation for patients with Wegovy and Ozempic eye damage side effects have been filed against the pharmaceutical company Novo Nordisk. These Wegovy and Ozempic eye damage lawsuits have received a boost, it seems, from some recent news out of Europe. From this November 21, 2025, article, "Denmark compensates … [Read more...]
Depo-Provera: Two Risk Factors for Meningioma Identified in 2025
A new 2025 medical study about Depo-Provera (depot medroxyprogesterone acetate) identified two risk factors for meningioma, a side effect associated with Depo-Provera injections. An article in the November 2025 edition of the medical journal JAMA Neurology, “Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US”, which reported the … [Read more...]
A Case of Primary Malignant Peritoneal Mesothelioma
Primary malignant mesothelioma (MPM) is a rare malignancy that arises from the epithelial cells that line visceral cavities. The primary pleural presentation is known as the most commonly seen presentation and is best recognized clinically. Less commonly, mesothelioma can arise from epithelial cells lining other visceral cavities, including the … [Read more...]
GLP-1 RA Drug NAION Cases: Medical and Legal Updates October 2025
GLP-1 RA Drug NAION Cases: Possible Drug Injury Lawsuits We are investigating possible drug injury lawsuits where people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss or blindness. Those GLP-1 RA drug NAION cases involve these … [Read more...]
Dupixent Legal and Medical Information About T-cell Lymphoma
In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect. We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on … [Read more...]
Chrysotile asbestos—the deadly consequences of a retreat from national bans
Many in the global clinical and research community reacted with horror to the June 18, 2025, news that the Trump administration was requesting that the US Environmental Protection Agency (US EPA) should “reconsider” the country’s ban on chrysotile asbestos. This ban had been previously enacted under the Biden presidency in 2024. Arguing that the … [Read more...]
Dupixent Cancer Lawsuits: Legal and Medical Update
We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. The Dupixent cancer lawsuits would be filed against the manufacturers of Dupixent, Sanofi and Regeneron, based on … [Read more...]
- 1
- 2
- 3
- …
- 23
- Next Page »